Cholesterol Conversations
ASCVD Management: Making the Case for Nonstatin Therapies
Feb 21, 2023
Join Drs. Neha Pagidipati, Christie Ballantyne, and Gregory Piazza in a lively discussion on ASCVD management, including nonstatin therapies, challenges in patient care, and alternative treatment options. Explore the evolution towards combination therapy, considerations for statin-intolerant patients, and the importance of personalized treatment plans. Delve into the efficacy and tolerability of PCSK9 inhibitors and azetamide for statin-hesitant patients, and the benefits of combining medications to lower LDL cholesterol effectively in high-risk patients.
21:25
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Assessing individual responses crucial for achieving LDL targets with statins alone.
- Nonstatin therapies like PCSK9 inhibitors or ezetimibe are essential for patients unresponsive to statin monotherapy.
Deep dives
Challenges in Achieving LDL Goals with Statin Therapy Alone
High-risk patients with atherosclerotic cardiovascular disease often struggle to reach LDL cholesterol targets with statins alone. Various factors, such as statin intolerance or insufficient dosage, hinder goal achievement. The discussion highlights the importance of assessing individual patient responses, exploring different statins or dosages, and considering non-statin therapies when statin monotherapy falls short.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
